“It will be primary prevention that can be applied to a large number of the population that will really make an impact to the incident numbers of type 1 diabetes,” said Ezio Bonifacio, PhD.

Wendy M. Kohrt, PhD, Karyn A. Esser, PhD, and K. Sreekumaran Nair, MD, principal investigators from the Molecular Transducers of Physical Activity Consortium, discussed how early data from animal studies is setting the stage for human studies.

The pandemic exacerbated gender inequities among health care providers. In the U.S., 73% of health care providers who tested positive for COVID-19 were women. The ADA’s network for female clinicians, scientists, educators, and other health professionals discussed the impact of this and strategies to close leadership gaps.

Experts in four rare forms of diabetes discussed strategies for diagnosing and treating patients with these atypical conditions during the Scientific Sessions. The session featured Janet B. McGill, MD, Marina Basina, MD, Armen Yerevanian, MD, and Mark S. Anderson, MD, PhD.

A panel of physician-scientists including Ralph A. DeFronzo, MD, Chantal Mathieu, MD, PhD, Tina Vilsbøll, MD, DMSc, and David D’Alessio, MD, discussed the current evidence for combination therapies in the treatment of type 2 diabetes.

Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC, Muthiah Vaduganathan, MD, MPH, Brendon Neuen, MBBS (Hons), MSc (Oxon), and David C. Wheeler, MD, FRCP, reviewed recent trial results demonstrating the safety and efficacy of SGLT2 inhibitors for both cardiovascular and renal treatment, and discussed how those trial results will help improve care for people…

Nigel A. Calcutt, PhD, Fabiana Picconi, MD, Karolina S. Khan, MD, PhD, and Kara R. Mizokami-Stout, MD, made up a panel of researchers who discussed some of the most challenging issues they face while investigating methods to prevent and treat diabetic neuropathies.

Camillo Ricordi, MD, FNAI, Thierry Berney, MD, A.M. James Shapiro, MD, PhD, and Piotr Witkowski, MD, PhD, explained what has led to pancreatic islet transplantation effectively halting in the United States while the procedure has become standard of care in much of the rest of the world.

“Stress is epidemic in the U.S. and other Western [countries], and most of our stressors are social,” said Carol A. Shively, PhD, in a session on the influence of social stress and social inequalities on metabolic health. She presented evidence based on animal models. Mika Kivimäki, PhD, FMedSci, presented evidence of the correlation between socioeconomic…

Investigators presented findings from the GRADE study comparing clinical outcomes of glimepiride, a sulfonylurea; sitagliptin, a DPP-4 inhibitor; insulin Lantus; and liraglutide, a GLP-1 receptor agonist. More than 70% of participants reached the primary metabolic endpoint.